The “Collaborative Outcomes Study on Health and Functioning during Infection Times” (COH-FIT), which involves almost 200 researchers from over 40 countries on six continents, aims to measure the impact of the COVID-19 on physical and mental health.
Supported by the SNF, this research project is based on the hypotheses that severe presentation of COVID-19 results from genetic predisposition and that transcriptomic profiling at an early stage may help predict adverse outcomes.
As part of the “Corona Accelerated R&D in Europe” (CARE) programme, the Allergy and Immunology Department at CHUV has secured funding of almost 5 million Swiss francs for its work aimed at isolating antibodies that neutralise the coronavirus.
Supported by the Swiss National Science Foundation (NSF) and in collaboration with the Federal Office of Public Health (FOPH), CHUV is coordinating Switzerland’s participation in the “Solidarity” study.
In conjunction with the École polytechnique fédérale de Lausanne (EPFL) and the Swiss Vaccine Research Institute (SVRI), CHUV has developed the blood test selected for conducting population studies in Switzerland.
To fight lymphoblastic leukaemia in children and young adults, the UNIL CHUV Oncology Department and our paediatric oncology consultation have developed an innovative immunotherapy in collaboration with Seattle Children's Hospital.
The CoLaus|PsyCoLaus study includes more than 6,700 inhabitants of the city of Lausanne in Switzerland followed for over 15 years. The results of the study have already given rise to more than 470 publications.